203 related articles for article (PubMed ID: 28288256)
1. Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials.
Whyte J; Woodcock J; Wang J
JAMA Intern Med; 2017 May; 177(5):724-727. PubMed ID: 28288256
[TBL] [Abstract][Full Text] [Related]
2. Tracking inclusion of women in clinical studies.
Wood SF
J Womens Health (Larchmt); 2009 Mar; 18(3):301-2. PubMed ID: 19231989
[No Abstract] [Full Text] [Related]
3. Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.
Shahid I; Khan MS; Sohail A; Khan SU; Greene SJ; Fudim M; Michos ED
JAMA Netw Open; 2022 Feb; 5(2):e220035. PubMed ID: 35212753
[TBL] [Abstract][Full Text] [Related]
4. News from the Society for Women's Health Research: FDA doing poor job of monitoring drugs for sex differences.
Greenberger P
J Womens Health Gend Based Med; 2001 Nov; 10(9):829-30. PubMed ID: 11747675
[No Abstract] [Full Text] [Related]
5. Women in clinical trials--a portfolio for success.
Buring JE
N Engl J Med; 2000 Aug; 343(7):505-6. PubMed ID: 10944570
[No Abstract] [Full Text] [Related]
6. Inclusion of Older People Reflective of Real-World Clinical Practice in Cardiovascular Drug Trials.
Caughey GE; Inacio MC; Bell JS; Vitry AI; Shakib S
J Am Heart Assoc; 2020 Nov; 9(21):e016936. PubMed ID: 33103558
[TBL] [Abstract][Full Text] [Related]
7. Working Together to Address Women's Health in Research and Drug Development: Summary of the 2017 Women's Health Congress Preconference Symposium.
Feuerstein IM; Jenkins MR; Kornstein SG; Lauer MS; Scott PE; Raju TNK; Johnson T; Devaney S; Lolic M; Henderson M; Clayton JA
J Womens Health (Larchmt); 2018 Oct; 27(10):1195-1203. PubMed ID: 30325292
[TBL] [Abstract][Full Text] [Related]
8. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
[TBL] [Abstract][Full Text] [Related]
9. There is no women's health crisis.
Satel SL
Public Interest; 1998; 130():21-33. PubMed ID: 11658109
[No Abstract] [Full Text] [Related]
10. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.
Sager PT; Seltzer J; Turner JR; Anderson JL; Hiatt WR; Kowey P; Prochaska JJ; Stockbridge N; White WB
Am Heart J; 2015 Apr; 169(4):486-95. PubMed ID: 25819855
[TBL] [Abstract][Full Text] [Related]
11. Between a rock and a hard place.
Demaria AN
J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
[No Abstract] [Full Text] [Related]
12. Women in clinical drug trials. An update.
Schmucker DL; O'Mahony MS; Vesell ES
Clin Pharmacokinet; 1994 Dec; 27(6):411-7. PubMed ID: 7882633
[No Abstract] [Full Text] [Related]
13. Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020.
Chen S; Li J
JAMA Netw Open; 2021 Mar; 4(3):e212640. PubMed ID: 33755163
[TBL] [Abstract][Full Text] [Related]
14. FDA lifts ban on women in early drug tests, will require companies to look for gender differences.
Cotton P
JAMA; 1993 Apr; 269(16):2067. PubMed ID: 8468748
[No Abstract] [Full Text] [Related]
15. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
Psaty BM; Weiss NS; Furberg CD; Koepsell TD; Siscovick DS; Rosendaal FR; Smith NL; Heckbert SR; Kaplan RC; Lin D; Fleming TR; Wagner EH
JAMA; 1999 Aug; 282(8):786-90. PubMed ID: 10463718
[No Abstract] [Full Text] [Related]
16. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
[TBL] [Abstract][Full Text] [Related]
17. Are surrogate markers adequate to assess cardiovascular disease drugs?
Temple R
JAMA; 1999 Aug; 282(8):790-5. PubMed ID: 10463719
[No Abstract] [Full Text] [Related]
18. The US Food and Drug Administration and Cardiovascular Medicine: Reflections and Observations.
Califf RM
Circulation; 2016 Aug; 134(7):501-3. PubMed ID: 27528644
[No Abstract] [Full Text] [Related]
19. Participation of women in clinical trials of drug therapies: a context for the controversies.
Prout MN; Fish SS
Medscape Womens Health; 2001 Oct; 6(5):1. PubMed ID: 11698923
[TBL] [Abstract][Full Text] [Related]
20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
Temple R
Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
